Cluster 16 · Visual Atlas

The Visual Evidence Atlas

Seventeen topics, 127 mobile-first slides. The visual companion to the educational clusters — neuroscience, myth-busting, practice, context, and the evidence rated condition by condition. Each entry pairs a visual walkthrough with a 90-second written brief. Educational information only, not medical advice.

90-second quick read · deeper research available

Need the deeper research library?

This is the 90-second cliff-note read on imicrodosing.net. For cited research context, terminology, and broader education, use the full .org research library.

Explore all full research topics →Browse related 90-second reads →

The neuroscience

ScienceNeuroplasticityPreclinical and perceptible-dose findings are relevant; microdosing implications remain uncertain.Open the atlas →ScienceDefault mode networkA brain-network model studied mainly at perceptible doses, not a guaranteed microdosing outcome.Open the atlas →ScienceThe 5-HT2A receptorA central receptor in psychedelic pharmacology; receptor activity alone does not prove benefit.Open the atlas →Science (frontier)PsychoplastogensCan you keep the brain rewiring and drop the trip? Olson's hypothesis is that the hallucination and the healing may be separable.Open the atlas →Single-paper deep diveCritical period reopeningA single 2023 Nature paper proposed a unifying mechanism for psychedelics: they reopen a childhood-like learning window, and how long the window stays open tracks how long the drug's effects last.Open the atlas →

Critical thinking

Critical thinkingMyths debunkedFour myths that follow people into microdosing — and where each one is wrong, partly right, or genuinely unresolved.Open the atlas →

The practice

PracticeSet, setting, integrationThe oldest framework in psychedelics, applied to the smallest doses.Open the atlas →PracticeTolerance & cyclingTolerance is documented, while consumer cycling schedules are not clinically standardized.Open the atlas →Cluster companionFormats comparedFormats differ in measurement and documentation, not proven clinical effectiveness.Open the atlas →

Context

ContextHistory & contextRoughly five thousand years in four eras: indigenous use, Western discovery, prohibition, and renaissance.Open the atlas →ContextThe reading listA starting curriculum, not a canon.Open the atlas →ContextUS legal landscapeFederal, state, and local rules differ and are reviewed against current official sources.Open the atlas →

Compared and rated

Cluster companionThe dose spectrumInformal effect labels do not translate into one reliable mushroom-weight scale.Open the atlas →Cluster companionMedication interactionsInteraction evidence is incomplete; personal medication decisions require qualified review.Open the atlas →Cluster companionSpecies & strainsNot all mushrooms are equal, and not all of a single mushroom is equal.Open the atlas →Cluster companionPsilocybin vs othersFour compounds often discussed together, with genuinely different mechanisms underneath.Open the atlas →Cluster companionEvidence per conditionObservational, controlled microdose, and full-dose evidence are separated condition by condition.Open the atlas →

Common questions

Answered directly

Q · 01

What is the Visual Evidence Atlas?

The Visual Evidence Atlas is a free, mobile-first section of imicrodosing.net containing 127 evidence slides across 17 topics. Each topic pairs a swipeable slide set with a 90-second written brief in the site's standard TL;DR, key-facts, evidence-tier, verdict, and FAQ format. It is the visual companion to the site's educational clusters.

Q · 02

Are these slides peer-reviewed?

The slides summarise published research and established frameworks, with the strongest claims anchored to named studies such as Ly et al. 2018 (Cell Reports) and Nardou et al. 2023 (Nature). The slides themselves are educational summaries, not peer-reviewed publications, and each topic states the evidence tier — strong, moderate, early, or anecdotal — for its claims.

Q · 03

Why present the evidence in a visual format?

Microdosing questions are often visual — a time course, a receptor, a comparison across drugs. Slides make these easier to grasp on a phone than dense text. Each slide is paired with descriptive text and a written brief so the same information is fully readable, indexable, and accessible without relying on the images alone.

Product-format context

For product-format context, see the iMicrodosing.com products and client support.

View products & support →